# Corrections, Sources, and Scope

> Contact the Editorial Desk — Alpha Peptides Australia — Contact Alpha Peptides Australia about Research Peptide Fundamentals research peptides, source corrections, terminology, and editorial scope.

**EDITORIAL DESK / CONTACT**

A contact route for evidence corrections and editorial questions—not product, prescribing, or recruitment enquiries.

## What belongs in an editorial note

The editorial desk welcomes concise corrections to source interpretation, compound terminology, citation placement, and statements about evidence maturity. The most useful message identifies the page and heading, quotes the short passage at issue, names the source already in the reference index or supplies enough bibliographic detail for later review, and explains the proposed correction.

Priority is given to errors that could change a reader's understanding of study population, model, endpoint, comparator, regulatory category, or safety signal. Typographic and accessibility issues are also welcome. New evidence may be noted for a future corpus review, but it cannot be added casually to a signed source set. That constraint protects traceability: claims change only when the underlying editorial corpus is deliberately reviewed.

## What this desk cannot provide

Alpha Peptides Australia does not answer personal medical questions, recommend compounds, interpret symptoms, provide human dosing, assess individual eligibility, locate suppliers, arrange prescriptions, or enrol participants into clinical trials. It does not verify commercial products or endorse clinics, pharmacies, laboratories, or brands.

A general editorial mailbox may be addressed as **editorial@alphapeptidesaustralia.com**. The address is presented for publication-facing correspondence; no response time is promised. Messages containing urgent health concerns belong with appropriate clinical or emergency services, not an editorial queue. Questions about formal research participation belong with the accountable investigators and contact details listed by the relevant registered study. Current Australian product or medicine status belongs with the applicable official regulatory record.

The boundary is intentional. A literature digest can clarify what a paper reports and how strongly it supports a claim. It cannot convert that summary into an individual decision, an approval determination, or a study-access pathway.

---

An independent Australian-facing evidence digest that maps peptide claims to their study design and regulatory boundary, never to a sale or personal prescription.